Research summaries for everyoneNot medical advice

Research updates · checked November 7, 2026

What changed, and when.

New trials, publications and regulatory decisions for the compounds in our library, newest first. Every entry links to its source.

November 2026

  1. Psoriatic arthritis data at ACR

    Lilly presents TOGETHER-PsA, a phase 3b study of ixekizumab with tirzepatide in psoriatic arthritis with obesity.

    Read the source
  2. TRIUMPH-4 at ACR Convergence

    Lilly presents the 68-week phase 3 TRIUMPH-4 trial in knee osteoarthritis pain as a plenary; knee data from TRIUMPH-1 follow on November 10.

    Read the source

October 2026

  1. First head-to-head phase 3

    Sponsor-reported TRANSCEND-T2D-2 results compare retatrutide with semaglutide 2 mg in type 2 diabetes over 80 weeks. Full results are not yet published.

    Read the source
  2. HHS interim compounding policy

    HHS published an enforcement-discretion policy covering BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500 for licensed pharmacies and physicians. Comments close November 13, 2026.

    Read the source
  3. Orthopaedic review

    A JAAOS review of BPC-157, thymosin beta-4 and TB-500 finds mostly preclinical evidence.

    Read the source
  4. Expert caution on clinical claims

    A commentary in Aesthetic Surgery Journal warns that mechanistic plausibility is not clinical validation.

    Read the source

September 2026

  1. TRIUMPH-1 and TRIUMPH-2 published

    TRIUMPH-1 appeared in NEJM and TRIUMPH-2 in The Lancet.

    Read the source

July 2026

  1. FDA advisory committee votes

    FDA’s Pharmacy Compounding Advisory Committee voted on seven peptides over July 23–24, recommending six and declining emideltide (DSIP).

    Read the source
  2. TRIUMPH-2 and TRIUMPH-3 topline

    Lilly reported topline results and said it plans to submit to FDA in Q1 2027.

    Read the source

April 2026

  1. Category 2 removals

    FDA announced the removal of 12 peptide substances from its Category 2 compounding list, effective about April 22, 2026. Removal is not approval.

    Read the source

February 2026

  1. Zepbound KwikPen

    FDA approved a four-dose, single-patient Zepbound pen.

    Read the source

January 2026

  1. Precursors compared head to head

    A randomized study in 65 adults found NR and NMN raised blood NAD+ over 14 days while nicotinamide did not.

    Read the source